The ORVAC Trial: A Phase IV, Double-blind, Randomised, Placebo-controlled Clinical Trial of a Third Scheduled Dose of RV1 Rotavirus Vaccine in Australian Indigenous Infants to Improve Protection Against Gastroenteritis
Phase of Trial: Phase IV
Latest Information Update: 13 Apr 2018
At a glance
- Drugs RIX 4414 (Primary)
- Indications Rotavirus infections
- Focus Therapeutic Use
- Acronyms ORVAC
- 21 Mar 2018 Status changed from not yet recruiting to recruiting.
- 05 Oct 2017 Planned initiation date changed from 1 Dec 2016 to 1 Oct 2017.
- 25 Oct 2016 New trial record